# Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

> **NCT02639091** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 36 (actual)

## Conditions studied

- Medical Oncology

## Interventions

- **DRUG:** BAY 94-9343
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02639091
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-03
- **Primary completion:** 2018-05-23
- **Final completion:** 2019-10-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639091, "Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02639091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*